Edinburgh Research Explorer

Improving the efficiency of the development of drugs for stroke

Research output: Contribution to journalLiterature reviewpeer-review

Original languageEnglish
Pages (from-to)371-377
Number of pages7
JournalInternational Journal of Stroke
Volume7
Issue number5
DOIs
Publication statusPublished - Jul 2012

Abstract

The mortality and morbidity associated with stroke makes the development of new drugs a research priority. Recent unsuccessful clinical trials have reduced enthusiasm for the development of neuroprotective drugs. Here, we use empirical evidence derived from systematic reviews of stroke drug development to identify stages of drug development which might be improved. We then propose exemplar strategies which may be helpful, along with some basic economic modelling of what the impact of such strategies might be. This suggests that relatively straightforward measures might reduce the costs of drug development by $5.8?bn or 31%.

    Research areas

  • ANIMAL-MODELS, translation, TISSUE-PLASMINOGEN ACTIVATOR, FOCAL CEREBRAL-ISCHEMIA, COST, EFFICACY, NEUROPROTECTION, pharmacoecomonics, neuroprotection, METAANALYSIS

ID: 7916818